EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials

Zehui Jiang, Wenxuan Sun, Rui Du, Rui Yang

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03451-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Zehui Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gobroad Healthcare Group, 20 Lize Road, Beijing, 100073, China. Hauptthemen laut MEDLINE: Maximum Tolerated Dose, United States Food and Drug Administration, Hematologic Neoplasms, Drug Approval. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Maximum Tolerated DoseUnited States Food and Drug AdministrationHematologic NeoplasmsDrug ApprovalNeoplasmsAntineoplastic AgentsHumansUnited StatesDose-Response Relationship, Drug

Stichwörter der Autor:innen

Biologics License ApplicationDose escalationFirst-in-humanNew Drug ApplicationPhase I clinical trial

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Gobroad Healthcare Group, 20 Lize Road, Beijing, 100073, China.
  • Gobroad Healthcare Group, 20 Lize Road, Beijing, 100073, China. rui.yang@gobroadaro.com.

Zitieren

APA

Jiang, Z., Sun, W., Du, R., & Yang, R. (2024). A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03451-2

Vancouver

Jiang Z, Sun W, Du R, Yang R. A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03451-2

BibTeX
@article{Jiang2024,
  author = {Jiang, Zehui and Sun, Wenxuan and Du, Rui and Yang, Rui},
  title = {A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03451-2}
}
Kostenlos starten →